Compare Gilead Sciences, Inc. (GILD) vs Vanguard Short Term Corporate Bond ETF (VCSH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Vanguard Short Term Corporate Bond ETF — how do they compare? Gilead Sciences, Inc. trades at $135.66 (market cap $163.51B), while Vanguard Short Term Corporate Bond ETF trades at $78.74. The key difference: Gilead Sciences, Inc. pays a 2.49% dividend while Vanguard Short Term Corporate Bond ETF pays none, and Gilead Sciences, Inc. is trading nearer its 52-week high, Vanguard Short Term Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.
| GILD | VCSH | |
|---|---|---|
Market Cap | $163.51B | — |
Sector | Health | Fixed Income |
52-Week High | $155.80 | $80.20 |
52-Week Low | $108.22 | $78.45 |
Enterprise Value | $178.05B | — |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
VCSH, the Vanguard Short-Term Corporate Bond ETF, trades at $78.715 with a slight 0.15% daily gain. Technical indicators show a bearish trend with moving averages signaling caution, while oscillators remain neutral. The ETF focuses on investment-grade corporate debt, offering a competitive yield and low expense ratio of 0.03% as highlighted by The Motley Fool on July 13, 2026. Recent institutional activity includes mixed stake adjustments, with Caldwell Trust boosting its position by 1,276.3% in Q4 2025 per SEC filings.
The outlook for VCSH is stable, benefiting from its short-duration bond focus amid a higher-rate environment, though the bearish technical trend and potential interest rate volatility pose risks. Its low costs and monthly dividends appeal to income-focused investors, but competition from treasury ETFs and tax-exempt alternatives requires careful consideration of individual tax situations and risk tolerance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Vanguard Short Term Corporate Bond ETF
VCSH tracks the Bloomberg U.S. 1-5 Year Corporate Bond Index, focusing on high-quality, investment-grade debt with short maturities. It is designed to offer higher income than Treasury bills with significantly lower interest rate sensitivity than intermediate or long-term bond funds.
Read more on VCSH →
